nasopharyngeal carcinoma

16 · 20 / page

Ask MedXY AI

Latest news

Tag

newsbiomarkersearly detection

Advancing Early Detection of Nasopharyngeal Carcinoma: Evaluating the Novel Anti-BNLF2b Antibody Test

By MedXY|Jul 11, 2026

This article critically appraises a multicenter study validating the Anti-BNLF2b antibody (P85-Ab) assay, highlighting its superior sensitivity and specificity for early nasopharyngeal carcinoma detection compared to established EBV-based b

Anti-EBV BNLF2b Antibody Shows High Accuracy for Outpatient Diagnosis of Suspected Nasopharyngeal Carcinoma

newsBNLF2bdiagnostic biomarker

nasopharyngeal carcinoma

Latest news

Advancing Early Detection of Nasopharyngeal Carcinoma: Evaluating the Novel Anti-BNLF2b Antibody Test

Anti-EBV BNLF2b Antibody Shows High Accuracy for Outpatient Diagnosis of Suspected Nasopharyngeal Carcinoma

Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma

Gut Microbiome Signatures Improve Diagnosis and Prognostic Stratification in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

Radiation-Induced OME: Bacterial Colonization Elevates Early Recurrence Risk Yet Lacks Long-Term Prognostic Value

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

Three-Year RATIONALE-309 Data Confirm Sustained Survival Benefit of First-Line Tislelizumab in Nasopharyngeal Carcinoma

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma

Proton Therapy Redefines the Standard of Care for Nasopharyngeal Carcinoma: Insights from a Landmark Case-Control Study

Intensity-Modulated Proton Therapy Reduces Acute Toxicity While Maintaining Oncologic Equivalence in Nasopharyngeal Carcinoma: A Five-Year Case-Control Analysis

Beyond PD-1: The Rise of Anti-LAG-3 Antibody LBL-007 in Fighting Nasopharyngeal Carcinoma

Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma

Induction vs Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

Sequential Chemoradiotherapy vs Induction Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Efficacy and Safety Insights from a Phase 3 Randomized Trial

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial